Objective: To evaluate safety and efficacy of ASCs infusion from healthy donors and daily cholecalciferol (VitD) supplementation in patients with recent-onset T1D, after a 6-month follow-up.

Methods: This is a phase II, prospective, one center, open trial, in which patients with recent onset T1D received one infusion of ASCs (1x106 cells/kg) and VitD 2000UI/day for 6 months. They were compared to controls with standard insulin therapy. C-peptide (CP) after mixed meal, insulin dose(UI/kg), HbA1c and CD45+CD3+CD4+FoxP3+T-cells frequencies (flow cytometry) were measured at baseline (T0) and after 3 (T3) and 6 months (T6).

Results: Eleven patients were included. Mean age and disease duration were 24.2 ± 5.2 years and 3.11 ± 0.88 months, respectively. Group 1 (n=7) received ASCs+VitD and group 2 (n=4) standard insulin therapy. Age, insulin dose, HbA1c and area under the curve (AUC) of CP were similar at T0 between groups (p=0.23, 0.23, 0.98 and 0.73, respectively). After intervention, group 1 had lower insulin requirement than group 2 at T3 (0.24±0.18 vs. 0.53±0.23IU/Kg, p=0.04) and T6 (0.24±0.15 vs. 0.66±0.33 UI/kg, p=0.04). Two patients in group 1 became transiently insulin free. HbA1C was lower in group 1 at T6 (6.77±0.79 vs. 8.75±0.95%; p=0.01). CP AUC was higher in group 1 at T3 (211.20 ± 100.42 vs. 106.05±47.25 ng/ml.min;p=0.04) and T6 (220.58 ± 97.06 vs. 63.37±37.96ng/ml.min, p=0.006). At T6, 6 patients in group 1 (85.7%) were in honeymoon phase (insulin dose ≤ 0.5IU/kg and HbA1c <7.5%) vs. none in group 2 (p=0.01). At T6 there was an inverse correlation between serum VitD and HbA1C (p=0.03; r=-0.66) and a positive correlation between VitD and CP AUC (p=0.02, r=0.67). CD45+CD3+CD4+FoxP3+ T-cells increased at T1 in group 1 (p=0.04), without differences at T3 and T6.

Conclusion: Allogenic ASCs infusion + VitD without immunosuppression was safe and may be an effective approach for the treatment of patients with recent onset T1D.


J.R. Dantas: None. D.B. Araujo: None. L.S. Baptista: None. D.L. Souto: None. K. Pereira: None. M.F. Pereira: None. C.S. Claudio-da-Silva: None. M.S. Mantuano: None. D.R. Daga: None. A.C. Senegaglia: None. C.K. Rebelatto: None. C.B. Couri: None. J.E. Oliveira: None. L. Zajdenverg: None. M. Rodacki: None.


Coordenação de Aperfeiçoamento de Pessoal de Nível Superior; Fundação de Amparo a Pesquisa do Rio de Janeiro

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.